Based on this regulatory mechanism, systemic co‐delivery of siCFL1 and sorafenib with reduction‐responsive nanoparticles can effectively silence CFL1 expression and significantly inhibit HCC patient‐derived xenografts tumor growth. This evidence concerns the gene CFL1 and hepatocellular carcinoma.